Featured
The Metabolic Fiat Standard: How GLP-1 Mandates, Biometric Licensing, and the Plant-Protein Paradox Are Rewiring the Fitness Economy
The FDA's approval of triple-agonist retatrutide, WADA's ban on non-peptide myostatin inhibitors, and UnitedHealth's cessation of CGM coverage for non...
Read Full Story →